JP2023543835A5 - - Google Patents

Info

Publication number
JP2023543835A5
JP2023543835A5 JP2023519659A JP2023519659A JP2023543835A5 JP 2023543835 A5 JP2023543835 A5 JP 2023543835A5 JP 2023519659 A JP2023519659 A JP 2023519659A JP 2023519659 A JP2023519659 A JP 2023519659A JP 2023543835 A5 JP2023543835 A5 JP 2023543835A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023519659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543835A (ja
JP7812848B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/052668 external-priority patent/WO2022072508A1/en
Publication of JP2023543835A publication Critical patent/JP2023543835A/ja
Publication of JP2023543835A5 publication Critical patent/JP2023543835A5/ja
Priority to JP2025187326A priority Critical patent/JP2026015391A/ja
Application granted granted Critical
Publication of JP7812848B2 publication Critical patent/JP7812848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023519659A 2020-09-30 2021-09-29 抗ｃｄ９４抗体及びその使用方法 Active JP7812848B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025187326A JP2026015391A (ja) 2020-09-30 2025-11-06 抗ｃｄ９４抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063085932P 2020-09-30 2020-09-30
US63/085,932 2020-09-30
US202063088926P 2020-10-07 2020-10-07
US63/088,926 2020-10-07
PCT/US2021/052668 WO2022072508A1 (en) 2020-09-30 2021-09-29 Anti-cd94 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025187326A Division JP2026015391A (ja) 2020-09-30 2025-11-06 抗ｃｄ９４抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2023543835A JP2023543835A (ja) 2023-10-18
JP2023543835A5 true JP2023543835A5 (enExample) 2024-10-07
JP7812848B2 JP7812848B2 (ja) 2026-02-10

Family

ID=80950868

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023519659A Active JP7812848B2 (ja) 2020-09-30 2021-09-29 抗ｃｄ９４抗体及びその使用方法
JP2025187326A Pending JP2026015391A (ja) 2020-09-30 2025-11-06 抗ｃｄ９４抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025187326A Pending JP2026015391A (ja) 2020-09-30 2025-11-06 抗ｃｄ９４抗体及びその使用方法

Country Status (10)

Country Link
US (2) US11795228B2 (enExample)
EP (1) EP4221752A4 (enExample)
JP (2) JP7812848B2 (enExample)
KR (1) KR20230104611A (enExample)
AU (1) AU2021352981A1 (enExample)
CA (1) CA3197662A1 (enExample)
IL (1) IL301764A (enExample)
MX (1) MX2023003685A (enExample)
WO (1) WO2022072508A1 (enExample)
ZA (1) ZA202303966B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119173536A (zh) * 2022-03-25 2024-12-20 德伦生物公司 抗cd94抗体和其使用方法
CN116178552B (zh) * 2022-12-30 2025-03-07 合肥天港免疫药物有限公司 抗cd94的抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US20070178106A1 (en) 2004-04-30 2007-08-02 Innate Pharma, S.A. Compositions and methods for enhancing nk cell activity
PT1831258E (pt) 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
CN101300272B (zh) * 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
KR20100110864A (ko) * 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
KR102047248B1 (ko) 2011-06-17 2019-11-21 노보 노르디스크 에이/에스 침식성 세포의 선택적 제거
RU2017105425A (ru) * 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2020205440A1 (en) 2019-03-29 2020-10-08 Dren Bio, Inc. Methods of reducing large granular lymphocyte and natural killer cell levels

Similar Documents

Publication Publication Date Title
JP7366543B2 (ja) Ｂｃｍａ結合分子及びその使用方法
JP6317788B2 (ja) 抗ｏｘ４０抗体およびそれを使用する方法
EP3763387B1 (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
JP5604311B2 (ja) 疾患治療剤
CN113454119B (zh) 抗btla抗体
JP2021525544A5 (enExample)
CN110662768B (zh) 治疗性抗cd40配体抗体
JP2016513467A5 (enExample)
HUE028962T2 (en) Active ingredient for treating disease
CN102027017A (zh) 一种治疗疾病的试剂
US12227583B2 (en) Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
JP7843824B2 (ja) 抗体および使用方法
JP2024535692A5 (enExample)
JP2022527084A5 (enExample)
JP2023543835A5 (enExample)
JP2023517794A5 (enExample)
JP2024543385A5 (enExample)
JP2024527576A5 (enExample)
US20250051440A1 (en) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
WO2022057910A1 (en) Combination therapies targeting c5ar and pd-1/pd-l1 pathways
JP2025510783A5 (enExample)
AU2023329055A1 (en) Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic
HK40087536A (zh) 抗cd40抗体组合治疗癌症
HK40045557A (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use